.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Colorcon
UBS
Boehringer Ingelheim
Fish and Richardson
Novartis
Farmers Insurance
Federal Trade Commission
AstraZeneca
Chinese Patent Office

Generated: September 20, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 9,045,519 protect, and when does it expire?


Patent ► Subscribe protects LEXISCAN and is included in one NDA. There has been one Paragraph IV challenge on Lexiscan.

This patent has twenty-seven patent family members in twenty-three countries.

Summary for Patent: ► Subscribe

Title:N-pyrazole A.sub.2A receptor agonists
Abstract: The present disclosure provides a process for the preparation of 2-adenosine N-pyrazole compounds exemplified by the structure shown below that are potent and selective agonists for A.sub.2A adenosine receptor, compositions comprising these compounds, and methods for using these compound to stimulate mammalian coronary vasodilatation for imaging the heart. ##STR00001##
Inventor(s): Zablocki; Jeff A. (Mountain View, CA), Elzein; Elfatih O. (Fremont, CA), Palle; Venkata P. (Pune, IN), Belardinelli; Luiz (Palo Alto, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:14/020,736
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,403,567 N-pyrazole A2A adenosine receptor agonists► Subscribe
7,655,637N-pyrazole A.sub.2A receptor agonists► Subscribe
7,183,264N-pyrazole A2A receptor agonists► Subscribe
7,144,872N-pyrazole A.sub.2A receptor agonists► Subscribe
6,642,210 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists► Subscribe
8,569,260N-pyrazole A.sub.2A receptor agonists► Subscribe
8,278,435N-pyrazole A2A receptor agonists► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI230161► Subscribe
Turkey200200588► Subscribe
Portugal1189916► Subscribe
New Zealand516334► Subscribe
Norway2011002► Subscribe
Norway322457► Subscribe
Norway20016350► Subscribe
MexicoPA01013325► Subscribe
Luxembourg91785► Subscribe
South Korea100463300► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Mallinckrodt
Fuji
Cantor Fitzgerald
Fish and Richardson
Federal Trade Commission
AstraZeneca
Medtronic
Baxter
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot